sponsored
PatientsVille.com Logo

PatientsVille

Methylprednisolone Medical Research Studies

Up-to-date List of Methylprednisolone Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Methylprednisolone Medical Research Studies

Rank Status Study
1 Unknown  Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Drug: Depomedrol;   Other: Blood drawing only;   Drug: Methotrexate and depomedrol;   Drug: Mycophenolate mofetil and depomedrol
Outcome Measures: To determine major biomarker patterns in lupus patients flaring on minimal background medications and compare to those flaring on typical background meds used in clinic and clinical trials;   Biomarkers of steroid efficacy and toxicity;   validation of disease activity and flare instruments in development;   Patient reported outcomes and validation of new lupus specific quality of life and patient reported outcome measures
2 Recruiting Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis
Condition: Acute Alcoholic Hepatitis
Interventions: Drug: Anakinra;   Drug: Pentoxifylline;   Drug: Zinc Sulfate;   Drug: Methylprednisolone
Outcome Measures: Death;   MELD score
3 Recruiting A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP.
Condition: Immune Thrombocytopenic Purpura
Interventions: Drug: Methylprednisolone and IVIG;   Drug: Placebo and IVIG
Outcome Measures: The rapidity of rise in Platelet Count;   Days to PC falling to < 20 x 109/L;   Adverse Effects of therapy;   Quality of life changes over time and between the treatment groups
4 Recruiting Treatment of Renal Sarcoidosis by Methylprednisolone Bolus
Condition: Renal Sarcoidosis
Intervention: Drug: Methylprednisolone bolus IV 15 mg/kg/d for 3 days.
Outcome Measures: Percentage of patients with a positive response defined by eGRF better than 100% compared to eGRF prior treatment or a normalization of renal function.;   Efficacy (eGFR, percentage of patients with a eGRF < 60 ml/min/1.73m²);   Extra-renal manifestations;   incidence of arrhythmias and cardiac conduction disease;   fragility fracture;   neuro-psychiatric troubles and infections;   number of renal and extra-renal relapses.;   Characterization of vitamin and calcium deficiencies by blood and urinary dosages
5 Not yet recruiting Effects and Safety of Infusion of Low-Doses of Methylprednisolone in Early ALI and ARDS in Children
Conditions: Acute Lung Injury;   Acute Respiratory Distress Syndrome
Interventions: Drug: Methylprednisolone Arm;   Drug: Sterile Saline Arm
Outcome Measures: Effects on pulmonary organ function;   Effects on extra-pulmonary organ function;   Effects on inflammatory process;   Effects on hospitalization-related outcomes
6 Unknown  Prednisolone and Acupuncture in Bell's Palsy: a Randomised, Placebo-controlled, Multicentre Trial in China
Condition: Bell's Palsy
Interventions: Drug: Prednisolone;   Device: acupuncture
Outcome Measures: Assessment of Facial function;   Neurology examination;   registration of ipsilateral pain
7 Recruiting Arthralgia of the Temporomandibular Joint. Pain Relief Following One Intra-articular Injection of Methylprednisolone
Conditions: Arthralgia;   TMJ
Interventions: Drug: Methylprednisolone;   Drug: Physiologic saline
Outcome Measures: VAS pain score change at maximal mouth opening;   VAS pain score change at jaw rest;   Instrument measures;   Adverse events
8 Recruiting Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis (MS) Relapses
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Methylprednisolone PO;   Drug: Methylprednisolone IV
Outcome Measure: At least 1 point-reduction on Kurtzke functional scale
9 Unknown  Efficacy of Moxifloxacin/Prednisolone in Prevention of Post Surgery Inflammation
Condition: Eye Infection/Inflammation Other
Interventions: Drug: moxifloxacin 0,5% + prednisolone 1%;   Drug: moxifloxacin/prednisolone combination
Outcome Measures: Day 15 Evaluation of Anterior Chamber;   day 15 physician´s follow-up impression of inflammatory reaction score
10 Unknown  Prednisolone Priming Study in Patients With Chronic Hepatitis B
Condition: Chronic Hepatitis B
Interventions: Drug: Prednisolone;   Drug: Placebo priming
Outcome Measure: The primary endpoint will be the 1-year HBe-Ag seroconversion rate with or without prednisolone priming.
11 Unknown  Methylprednisolone Addition in IVF Treatment of Infertile Couples
Condition: In Vitro Fertilization
Intervention: Other: In vitro fertilization treatment for infertility
Outcome Measures: Progesterone rise above 1.5ng.ml on the day of HCG;   Clinical pregnancy rate
12 Unknown  Prednisolone Pharmacokinetics in Severe Asthma
Condition: Asthma
Intervention: Drug: prednisolone
Outcome Measures: serum prednisolone levels over 24 hours;   change in FEV1 24 hours post prednisolone;   changes in eNO, sputum eosinophils and inflammatory mediators over 24 hours;   difference between day 1 and day 14 in serum prednisolone levels;   difference in FEV1 between day 1 and day 14;   difference in inflammatory markers between day 1 and day 14;   changes in asthma control symptoms before and after treatment
13 Not yet recruiting Prevention of Noise-induced Hearing Loss
Condition: Noise-induced Hearing Loss
Interventions: Drug: Zonisamide;   Drug: Methylprednisolone
Outcome Measures: Pure Tone Thresholds;   DPOAE;   Pure tone thresholds
14 Recruiting Study to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse
Condition: Multiple Sclerosis
Interventions: Drug: Methylprednisolone 1250 mg/24h x3 days;   Drug: Oral Methylprednisolone 625 mg/24h x3 days
Outcome Measures: Disability scale of Kurtzke EDSS score;   Adverse events / tolerability;   The number and volume of active lesions (measured by the T2 or gadolinium enhancement), the number of new active lesions and the percentage of active lesions at baseline that becomes black holes;   Questionnaire MSQOL-54
15 Unknown  A Proof of Concept Study to Determine the Local Delivery and Efficacy of Nanocort
Condition: Atherosclerosis
Interventions: Drug: Nanocort;   Drug: Methylprednisolone;   Drug: Placebo
Outcome Measures: Quantity of PEG liposomes in the atherosclerotic plaque and/ or in atherosclerotic macrophages as determined with a PEG antibody quantitative sandwich ELISA.;   Differences between TNF-alpha levels in the supernatant of isolated macrophages from the atherosclerotic tissue as determined by quantitative sandwich ELISA;   Concentration of corticosteroids in plaque.
16 Unknown  The Efficacy of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease
Condition: Behcet's Disease
Interventions: Drug: methylorednisolone;   Other: dextrose water 5%
Outcome Measures: OCULAR IBDDAM INDEX;   VISUAL ACUITY;   Inflammation in retin;   Inflammation in posterior chamber;   inflammation in anterior chamber
17 Recruiting Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients
Conditions: Healthy Volunteers;   Multiple Sclerosis
Interventions: Drug: 2B3-201;   Drug: Placebo;   Drug: Methylprednisolone hemisuccinate
Outcome Measures: Number of subjects with adverse events as a measure of safety and tolerability of 2B3-201;   Pharmacokinetics in plasma of intravenously administered 2B3-201 in terms of Cmax, Volume of distribution, half-life (T1/2), area under the plasma concentration-time curve (AUC), Clearance (CL);   Measure changes in central nervous system (CNS) functioning after intravenous administration of 2B3-201 by using the Neurocart test battery;   Changes in levels of Hypothalamic-pituitary-adrenal (HPA) axis hormones as a measure of pharmacodynamic effects of 2B3-201 in comparison to free Methylprednisolone hemisuccinate and placebo;;   Changes in levels of fasting blood glucose as a measure of pharmacodynamic effects of 2B3-201 in comparison to free Methylprednisolone hemisuccinate and placebo;;   Changes in levels of osteocalcin concentrations as a measure of pharmacodynamic effects of 2B3-201 in comparison to free Methylprednisolone hemisuccinate and placebo;;   Changes in levels of lymphocyte count as a measure of pharmacodynamic effects of 2B3-201 in comparison to free Methylprednisolone hemisuccinate and placebo;;   Changes in levels of complement factors during infusion as a measure of pharmacodynamic effects of 2B3-201 in comparison to free Methylprednisolone hemisuccinate and placebo;
18 Unknown  Steroids in Patients With Early ARDS
Conditions: Acute Lung Injury;   ARDS, Human
Interventions: Drug: Methylprednisolone;   Other: Normal saline intravenously and vitamin B1 per os
Outcome Measures: The primary aim is to determine if low-dose Methylprednisolone infusion, compared to placebo, will reduce all cause 28-day mortality, defined as the proportion of patients alive in each group on study day 28 at midnight.;   The secondary aims are the effects of treatment on: a. Systemic inflammation b. Duration of mechanical ventilation c. Multiple organ dysfunction syndrome d. Duration of ICU and hospital stay e. Cardiovascular morbidity-mortality f. Complications
19 Unknown  Ciclosporin in the Management of New Type 1 Reactions in Leprosy
Condition: Leprosy
Interventions: Drug: Ciclosporin;   Drug: Prednisolone
Outcome Measures: improvement in nerve function;   incidence of adverse effects;   Skin lesion inflammation improvement;   rate of improvement of reaction;   Time to next reactional episode;   extra prednisolone needed to control reaction
20 Not yet recruiting Randomize Controlled Phase 3, Cross-over Trial of Dexamethasone-induced Hiccup in Chemotherapy Patients Treated by Methylprednisolone Rotation
Condition: Dexamethasone-induced Hiccup in Chemotherapy
Intervention: Drug: Methylprednisolone
Outcome Measures: The intensities of hiccups;   The intensities of emesis

These studies may lead to new treatments and are adding insight into Methylprednisolone etiology and treatment.

A major focus of Methylprednisolone research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Methylprednisolone